It is unsafe to consume alcohol with Vedilol.
CONSULT YOUR DOCTOR
Vedilol may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
SAFE IF PRESCRIBED
Vedilol is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Vedilol may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
SAFE IF PRESCRIBED
Vedilol is safe to use in patients with kidney disease. No dose adjustment of Vedilol is recommended. However, inform your doctor if you have any underlying kidney disease. Regular monitoring of blood pressure is recommended for dose adjustment.
Vedilol should be used with caution in patients with liver disease. Dose adjustment of Vedilol may be needed. Please consult your doctor. Use of Vedilol is not recommended in patients with severe liver disease.
Vedilol is a medicine used to treat high blood pressure, heart related chest pain (angina) and heart failure. It works by relaxing the blood vessels, so blood can flow more easily to the heart. Lowering blood pressure helps to prevent future heart attack and stroke. Vedilol should be taken with food. You should take it in the dose and duration as advised by the doctor. It is important to take it even if you feel well or if your blood pressure is controlled. You should not stop this medicine without talking to the doctor as your condition could get worse. Thus, your doctor will decide the time period till which you need to take this medicine. Making some changes in your lifestyle will help in improving your condition. These may include regular exercise, losing weight, smoking cessation, reducing alcohol intake, and reducing the amount of salt in your diet as advised by your doctor. This medicine is tolerated well by most patients but it has few side effects also. Some patients may experience dizziness, so you should avoid driving after taking the medicine. Other side effects include headache and tiredness. Let your doctor know if these side effects bother you or do not go away. You should keep monitoring your blood pressure as this medicine may reduce it. Before taking this medicine, let your doctor know if you have any heart or kidney disease. Pregnant or breastfeeding mothers should also consult their doctor before taking it.
Uses of Vedilol
- Hypertension (high blood pressure)
- Angina (heart-related chest pain)
- Heart failure
Side effects of Vedilol
- Decreased blood pressure
How to use Vedilol
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Vedilol is to be taken with food.
How Vedilol works
Vedilol is an alpha and beta blocker. It works by slowing down the heart rate and relaxing blood vessels which makes the heart more efficient at pumping blood around the body.
- It should be taken with food.
- Check your blood pressure 1 week after starting Vedilol, and inform your doctor if it has not improved.
- Vedilol may cause dizziness or sleepiness. Do not drive or do anything requiring concentration until you know how it affects you.
- It is best to avoid drinking alcohol while taking Vedilol as it may make the side effects worse.
- Do not stop taking Vedilol suddenly as it can cause your blood pressure to rise suddenly, thereby increasing the risk of heart attack and stroke.
Hypertension, Congestive heart failure, Myocardial infarction, Left ventricular dysfunction, Angina pectoris
Should be taken with food.
Congestive Heart Failure Immediate release 3.125 mg PO q12hr for 2 weeks, then increased every 2 weeks as tolerated to 6.25 mg, 12.5 mg, or 25 mg PO twice daily Maximum recommended dosage (mild-to-moderate heart failure): <85 kg, 25 mg PO q12hr; >85 kg: 50 mg PO twice daily Maximum recommended dosage (severe heart failure): 25 mg PO twice daily Extended release 10 mg/day PO; maintained for 1-2 weeks if tolerated; may be increased to 20 mg/day, 40 mg/day, or 80 mg/day PO if necessary Hypertension Immediate release: 6.25 mg PO twice daily initially; after 7-14 days, increased as tolerated, first to 12.5 mg PO twice daily and then to 25 mg PO twice daily Extended release: 20 mg/day PO; maintained for 1-2 weeks if tolerated; may be increased to 40 mg/day PO if necessary; not to exceed 80 mg/day PO Left Ventricular Dysfunction Following Myocardial Infarction Immediate release: 3.125-6.25 mg PO q12hr initially; after 3-10 days, increased as tolerated, first to 12.5 mg PO q12hr and then to 25 mg PO q12hr (target dosage) Extended release: 10-20 mg/day PO; increased every 3-10 days as tolerated up to 80 mg/day PO (target dosage) Angina pectoris 25-50 mg PO twice daily Hepatic impairment: Contraindicated in severe liver impairment
Safety and efficacy not established
Renal impairment: No dosage adjustments necessary
Hypersensitivity; severe chronic heart failure, bronchial asthma or related bronchospastic conditions; severe hepatic impairment. Patients with NYHA class IV cardiac failure, 2nd or 3rd ° AV block, sick sinus syndrome (unless a permanent pacemaker is in place), cardiogenic shock or severe bradycardia. Lactation.
Mode of Action
Carvedilol is a nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity. It exerts antihypertensive effect partly by reducing total peripheral resistance and vasodilation.
Avoid abrupt withdrawal as it may precipitate thyroid storm or exacerbate hyperthyroidism. Liver injury; vascular disease, renal failures, suspected phaeochromocytoma and prinzmetal's variable angina; worsening cardiac failure or fluid retention during increase in dosage of carvedilol; diabetic patients. Pregnancy. Lactation: Unknown whether drug is excreted in milk; not recommended
>10% Dizziness (2-32%),Fatigue (4-24%),Hypotension (9-20%),Weight gain (10-12%),Hyperglycemia (5-12%),Diarrhea (1-12%) 1-10% Bradycardia (2-10%),Nausea (2-9%),Cough (5-8%),Headache (5-8%),Atrioventricular block, edema (1-7%),Angina (1-6%),Hpercholesterolemia (1-4%),Hypertriglyceredemia (1%),Vomiting (1-6%),Dyspnea (>3%),Syncope (3%),Rhinitis (2%) Frequency Not Defined Hypertension,Palpitations,Insomnia,Somnolence,Skin rash,Hepatotoxicity,Impotence,Bronchospasm,Rales,Depression,Decreased exercise tolerance,Raynaud phenomenon,Increased triglyceride levels and insulin resistance with decreased high-density lipoprotein (HDL) levels
Pregnancy Category Note
Pregnancy Available data in pregnant women are insufficient to determine whether there are drug-associated risks of adverse developmental outcomes; there are risks to mother and fetus associated with poorly controlled hypertension in pregnancy; the use of beta blockers during third trimester of pregnancy may increase risk of hypotension, bradycardia, hypoglycemia, and respiratory depression in neonates; in animal reproduction studies, there was no evidence of adverse developmental outcomes at clinically relevant doses; observe newborns for symptoms of hypotension, bradycardia, hypoglycemia, and respiratory depression and manage accordingly Hypertension in pregnancy increases maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section and post-partum hemorrhage); hypertension increases fetal risk for intrauterine growth restriction and intrauterine death; pregnant women with hypertension should be carefully monitored and managed accordingly Lactation There are no data on presence of carvedilol in human milk, effects on breastfed infant, or on milk production; drug is present in the milk of lactating rats; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from treatment or from underlying maternal condition
Decreased serum levels w/ rifampicin. Combination w/ Ca channel blockers (e.g. verapamil and diltiazem) can lead to bradycardia and myocardial depression. Potentiates insulin-induced hypoglycaemic action. May increase hypoglycaemic effects of antidiabetic agents. Increased risk of bradycardia w/ digoxin. Increased risk of hypotension and bradycardia w/ reserpine, MAOIs, clonidine. May increase ciclosporin concentrations. Concurrent use w/ ether, cyclopropane, trichloroethylene may increase the risk of hypotension and heart failure.
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.